242 related articles for article (PubMed ID: 30661420)
1. Co-crystallization for enhanced dissolution rate of bicalutamide: preparation and evaluation of rapidly disintegrating tablets.
Essa EA; Elbasuony AR; Abdelaziz AE; El Maghraby GM
Drug Dev Ind Pharm; 2019 Aug; 45(8):1215-1223. PubMed ID: 30661420
[No Abstract] [Full Text] [Related]
2. Sucralose as co-crystal co-former for hydrochlorothiazide: development of oral disintegrating tablets.
Arafa MF; El-Gizawy SA; Osman MA; El Maghraby GM
Drug Dev Ind Pharm; 2016 Aug; 42(8):1225-33. PubMed ID: 26555927
[TBL] [Abstract][Full Text] [Related]
3. Formation of bicalutamide nanodispersion for dissolution rate enhancement.
Li C; Li C; Le Y; Chen JF
Int J Pharm; 2011 Feb; 404(1-2):257-63. PubMed ID: 21093558
[TBL] [Abstract][Full Text] [Related]
4. Xylitol as a potential co-crystal co-former for enhancing dissolution rate of felodipine: preparation and evaluation of sublingual tablets.
Arafa MF; El-Gizawy SA; Osman MA; El Maghraby GM
Pharm Dev Technol; 2018 Jun; 23(5):454-463. PubMed ID: 27681386
[TBL] [Abstract][Full Text] [Related]
5. Enhanced dissolution of solid dispersions containing bicalutamide subjected to mechanical stress.
Szafraniec J; Antosik A; Knapik-Kowalczuk J; Chmiel K; Kurek M; Gawlak K; Paluch M; Jachowicz R
Int J Pharm; 2018 May; 542(1-2):18-26. PubMed ID: 29481948
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of bicalutamide-poloxamer F68 solid dispersion systems.
Sancheti PP; Vyas VM; Shah M; Karekar P; Pore YV
Pharmazie; 2008 Aug; 63(8):571-5. PubMed ID: 18771004
[TBL] [Abstract][Full Text] [Related]
7. Solid-state characterization and dissolution properties of bicalutamide-beta-cyclodextrin inclusion complex.
Patil AL; Pore YV; Kuchekar BS; Late SG
Pharmazie; 2008 Apr; 63(4):282-5. PubMed ID: 18468387
[TBL] [Abstract][Full Text] [Related]
8. Spherical agglomeration to improve dissolution and micromeritic properties of an anticancer drug, Bicalutamide.
Dalvadi H; Parmar K; Yadav S
Drug Dev Ind Pharm; 2019 Jun; 45(6):968-980. PubMed ID: 30784326
[TBL] [Abstract][Full Text] [Related]
9. Planetary ball milling and supercritical fluid technology as a way to enhance dissolution of bicalutamide.
Szafraniec J; Antosik A; Knapik-Kowalczuk J; Kurek M; Syrek K; Chmiel K; Paluch M; Jachowicz R
Int J Pharm; 2017 Nov; 533(2):470-479. PubMed ID: 28363855
[TBL] [Abstract][Full Text] [Related]
10. Tabletting solid dispersions of bicalutamide prepared using ball-milling or supercritical carbon dioxide: the interrelationship between phase transition and
Antosik-Rogóż A; Szafraniec-Szczęsny J; Gawlak K; Knapik-Kowalczuk J; Paluch M; Jachowicz R
Pharm Dev Technol; 2020 Nov; 25(9):1109-1117. PubMed ID: 32686538
[TBL] [Abstract][Full Text] [Related]
11. How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions.
Pacult J; Rams-Baron M; Chmiel K; Jurkiewicz K; Antosik A; Szafraniec J; Kurek M; Jachowicz R; Paluch M
Eur J Pharm Sci; 2019 Aug; 136():104947. PubMed ID: 31170526
[TBL] [Abstract][Full Text] [Related]
12. Controlled precipitation for enhanced dissolution rate of flurbiprofen: development of rapidly disintegrating tablets.
Essa EA; Elmarakby AO; Donia AMA; El Maghraby GM
Drug Dev Ind Pharm; 2017 Sep; 43(9):1430-1439. PubMed ID: 28402193
[TBL] [Abstract][Full Text] [Related]
13. Amorphous Formulation and in Vitro Performance Testing of Instantly Disintegrating Buccal Tablets for the Emergency Delivery of Naloxone.
Alqurshi A; Kumar Z; McDonald R; Strang J; Buanz A; Ahmed S; Allen E; Cameron P; Rickard JA; Sandhu V; Holt C; Stansfield R; Taylor D; Forbes B; Royall PG
Mol Pharm; 2016 May; 13(5):1688-98. PubMed ID: 26977787
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of rapidly dissolving buccal films of naftopidil:
Elagamy HI; Essa EA; Nouh A; El Maghraby GM
Drug Dev Ind Pharm; 2019 Oct; 45(10):1695-1706. PubMed ID: 31418592
[No Abstract] [Full Text] [Related]
15. Understanding the performance of melt-extruded poly(ethylene oxide)-bicalutamide solid dispersions: characterisation of microstructural properties using thermal, spectroscopic and drug release methods.
Abu-Diak OA; Jones DS; Andrews GP
J Pharm Sci; 2012 Jan; 101(1):200-13. PubMed ID: 21905037
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes.
Desai C; Prabhakar B
Drug Dev Ind Pharm; 2015; 41(10):1589-607. PubMed ID: 25350555
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the Dissolution Mechanisms of Amorphous Bicalutamide Solid Dispersions via Real-Time Raman Mapping.
Tres F; Patient JD; Williams PM; Treacher K; Booth J; Hughes LP; Wren SA; Aylott JW; Burley JC
Mol Pharm; 2015 May; 12(5):1512-22. PubMed ID: 25872658
[TBL] [Abstract][Full Text] [Related]
18. Nanosized bicalutamide and its molecular structure in solvents.
Le Y; Ji H; Chen JF; Shen Z; Yun J; Pu M
Int J Pharm; 2009 Mar; 370(1-2):175-80. PubMed ID: 19101616
[TBL] [Abstract][Full Text] [Related]
19. Formulation and optimization of drug-loaded mesoporous silica nanoparticle-based tablets to improve the dissolution rate of the poorly water-soluble drug silymarin.
Ibrahim AH; Smått JH; Govardhanam NP; Ibrahim HM; Ismael HR; Afouna MI; Samy AM; Rosenholm JM
Eur J Pharm Sci; 2020 Jan; 142():105103. PubMed ID: 31648050
[TBL] [Abstract][Full Text] [Related]
20. Liquid antisolvent precipitation process for solubility modulation of bicalutamide.
Meer TA; Sawant KP; Amin PD
Acta Pharm; 2011 Dec; 61(4):435-45. PubMed ID: 22202202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
